Astellas Venture Management is a venture capital firm in Menlo Park that prefers to invest in companies within the biotechnology sector. Founded 1999 in Menlo Park, California, the firm invests in early stage ventures, late stage ventures, and private equity. The notable investment portfolio of Astellas Venture Management includes TScan Therapeutics, Heartseed, CODA Biotherapeutics, Oncorus, Cleave Therapeutics, Twentyeight-Seven Therapeutics, Effector Therapeutics, and Oncorus. As of January 2020, Astellas Venture Management has made 41 investments and 9 exits. Their most recent investment was on Jan 10, 2020, when TScan Therapeutics raised $35M.